Subscribe
Urology Practice Management - April 2015, Vol 4, No 2 - ACCC: Patient and Provider Access
Leah Ralph
Manager
Director of Health Policy
Association of Community Cancer Centers

On February 12, the US Department of Health & Human Services announced its much-anticipated Oncology Care Model, developed by the Centers for Medicare & Medicaid (CMS) Innovation Center as part of the broader effort to lower healthcare costs and tie reimbursement to quality and value. The Association of Community Cancer Centers has been conducting an in-depth analysis, and the model generally looks similar to the discussion draft made available in August last year; although the model contains many positive elements, many questions still remain.

At its core, the Oncology Care Model looks similar to a patient-­centered oncology medical home or accountable care organization, with a target expenditure and shared savings component that encompasses the total cost of patient care during a particular period of treatment. The model is a voluntary, 5-year program slated to begin in spring 2016. Physician group practices, hospital-based practices (except for prospective payment system–exempt hospitals), and solo practitioners who furnish cancer chemotherapy are eligible to participate.

Payments will be based on a 6-month episode of chemotherapy treatment that is triggered by the administration of a preset list of chemotherapy drugs, and will take into account all Part A and Part B, and some Part D expenditures for that patient during the episode. In addition to a fee-for-service payment, providers will receive a care coordination payment to improve quality of care ($160 per patient, per month during the episode) and, to incentivize lower costs, a performance-based payment that will be based on the difference between a risk-adjusted target price and actual expenditures during the episode. The payment arrangement is 1-sided risk, with the option of converting to a 2-sided risk in the third year.

Importantly, the care model is a multipayer model in which commercial payers and state Medicaid agencies are encouraged to participate. Aligning financial incentives by engaging multiple payers will leverage the opportunity to transform oncology care across a broader population. During its process of selecting practices to participate, CMS will favor those that participate with other payers in addition to Medicare. Practices will also have to meet certain quality metrics and undergo practice transformation requirements, including effective use of electronic health records, providing 24-hour access to practitioners who can consult the patient’s medical record in real time, developing comprehensive patient care plans, offering patient navigation services, and targeting continuous quality improvement.

Although we were pleased to see much of the Association of Community Cancer Centers’ feedback incorporated into the final version of this model—and we appreciated the opportunity to provide meaningful input before the model was finalized—our dialogue with CMS is ongoing. Our members continue to have questions about the benchmarking methodology, specifics on the quality metrics and practice transformation requirements, eligibility to participate in the model, and more. We continue to work with CMS to secure answers to these questions.

If your practice is interested in participating, or considering participation, we encourage you to submit a nonbinding letter of intent to CMS by the deadline of May 7, 2015. We anticipate that CMS will continue to provide additional guidance until the final application deadline of June 18, 2015.

Related Items
New Clarity on the 340B Drug Pricing Program: Was It Worth the Wait?
Leah Ralph
Oncology Practice Management - December 2015, Vol 5, No 9 published on December 22, 2015 in ACCC: Patient and Provider Access
Recognizing Value in Advance Care Planning
Maureen Leddy, JD
Oncology Practice Management - November 2015, Vol 5, No 8 published on November 11, 2015 in ACCC: Patient and Provider Access
State Innovations in Healthcare Reform
Maureen Leddy, JD
Oncology Practice Management - October 2015, Vol 5, No 7 published on October 13, 2015 in ACCC: Patient and Provider Access
States’ Approaches to Managing Cancer Drug Costs—Implications for Value-Based Treatment Decisions
Maureen Leddy, JD
Oncology Practice Management - September 2015, Vol 5, No 6 published on September 1, 2015 in ACCC: Patient and Provider Access
SGR Is Over: What’s Next for Providers?
Maureen Leddy, JD
Oncology Practice Management - June 2015, Vol 5, No 5 published on June 23, 2015 in ACCC: Patient and Provider Access
Rest in Peace, SGR
Leah Ralph
Oncology Practice Management - May 2015, Vol 5, No 4 published on May 14, 2015 in ACCC: Patient and Provider Access
Bringing the Oncology Care Model into Focus Patient and Provider Access
Leah Ralph
Oncology Practice Management - April 2015, Vol 5, No 3 published on April 17, 2015 in ACCC: Patient and Provider Access
Transforming Medicare Payments: Ambitious New Goals
Leah Ralph
Oncology Practice Management - March 2015, Vol 5, No 2 published on March 26, 2015 in ACCC: Patient and Provider Access
2014 Election Is in the Books: What Will It Mean for Healthcare in 2015?
Leah Ralph
Oncology Practice Management - December 2014, Vol 4, No 8 published on December 18, 2014 in ACCC: Patient and Provider Access
2014 Election Is in the Books: What Will It Mean for Healthcare in 2015?
Leah Ralph
Urology Practice Management - December 2014, Vol 3, No 6 published on November 26, 2014 in ACCC: Patient and Provider Access
Last modified: April 14, 2015
  • American Health and Drug Benefits
  • Association for Value Based Cancer Care
  • Lynx CME
  • Oncology Practice Management
  • Rheumatology Practice Management

Search